Anzeige
Meldung des Tages: Erste Genehmigung für Tiefseebergbau seit 1980: Warum dieser Meilenstein für den nächsten Small-Cap-Akteur wichtig ist

Biohaven News

Aktie
WKN:  A3DVH7 ISIN:  VGG1110E1079 US-Symbol:  BHVN Branche:  Biotechnologie Land:  USA
9,59 $
+0,00 $
0,00%
8,1721 € 01:00:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
957,79 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Biohaven News

16.07.25 - PR Newswire
Rosen Law Firm Urges Biohaven Ltd. (NYSE: BHVN) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm Urges Biohaven Ltd. (NYSE: BHVN) Stockholders to Contact the Firm for Information About Their Rights PR Newswire
16.07.25 - PR Newswire
BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm
BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
16.07.25 - PR Newswire
Shareholder Alert: Robbins LLP Informs Investors of the Biohaven Ltd. Corporation Class Action
Shareholder Alert: Robbins LLP Informs Investors of the Biohaven Ltd. Corporation Class Action PR Newswire
22.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN PR Newswire
12.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN PR Newswire
01.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN PR Newswire
29.05.25 - PR Newswire
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-​Penetrant TYK2/JAK1 Inhibitor PR Newswire
28.05.25 - PR Newswire
Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)
Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained ...
28.05.25 - PR Newswire
Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors
Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel ...
26.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN PR Newswire
20.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN PR Newswire
14.05.25 - PR Newswire
FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia
FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia PR Newswire
12.05.25 - PR Newswire
Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments
Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments PR Newswire

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »